Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to -$46.4 million.

  • Corcept Therapeutics' Cash from Financing Activities fell 12005.03% to -$46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$193.7 million, marking a year-over-year decrease of 74153.96%. This contributed to the annual value of -$28.3 million for FY2024, which is 8093.84% up from last year.
  • As of Q3 2025, Corcept Therapeutics' Cash from Financing Activities stood at -$46.4 million, which was down 12005.03% from -$102.9 million recorded in Q2 2025.
  • Corcept Therapeutics' Cash from Financing Activities' 5-year high stood at $766000.0 during Q4 2023, with a 5-year trough of -$207.0 million in Q4 2021.
  • In the last 5 years, Corcept Therapeutics' Cash from Financing Activities had a median value of -$14.0 million in 2022 and averaged -$36.1 million.
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first tumbled by 3121149.77% in 2021, then surged by 135573.77% in 2023.
  • Over the past 5 years, Corcept Therapeutics' Cash from Financing Activities (Quarter) stood at -$207.0 million in 2021, then surged by 99.97% to -$61000.0 in 2022, then surged by 1355.74% to $766000.0 in 2023, then crashed by 695.82% to -$4.6 million in 2024, then tumbled by 916.94% to -$46.4 million in 2025.
  • Its Cash from Financing Activities was -$46.4 million in Q3 2025, compared to -$102.9 million in Q2 2025 and -$39.8 million in Q1 2025.